SecBot SecBot
SECBOTREPLAY Home › Report › BIO

BIO · Q3 non-GAAP EPS $2.65

BIO-RAD LABORATORIES, INC. · 8-K filed Nov 4, 2026 at 16:16 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Nov 4, 2026 at 16:16 ET

Bio-Rad reported Q3 2026 non-GAAP EPS of $2.65, beating the $2.23 consensus by 18.8%, and revenue of $656.4M, slightly above the $650.0M estimate. Non-GAAP operating margin expanded 100bps YoY to 12.8%, and the company maintained its full-year 2026 guidance for currency-neutral revenue decline of 3.0% to growth of 0.5% and non-GAAP operating margin of 10.0-12.0%. GAAP results included a $49.8M impairment charge and $77.2M in restructuring costs, driving a GAAP operating loss.

  • Q3 2026 non-GAAP EPS $2.65 vs consensus $2.23 (beat by 18.8%)
  • Q3 2026 revenue $656.4M vs consensus $650.0M (beat by 1.0%)
  • Reported revenue +0.5% YoY; currency-neutral revenue +0.7% YoY
  • Non-GAAP gross margin 54.5% (+100bps YoY); non-GAAP operating margin 12.8% (+100bps YoY)

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access